Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 97.47% is 73% above its 5-year average of 56.26%, near the high end of its 5-year range (0.00%–102.30%).
0.30% above its 12-month average of 97.18%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 95.59%.
GROSS MARGIN
97.47%
GROSS MARGIN AVG TTM
97.18%
GROSS MARGIN AVG 3Y
67.81%
GROSS MARGIN AVG 5Y
56.26%
GROSS MARGIN AVG 10Y
99.41%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.30%
CURRENT VS 3Y AVG
+43.75%
CURRENT VS 5Y AVG
+73.26%
CURRENT VS 10Y AVG
-1.95%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+135.55%
vs the sector median at left
Syndax Pharmaceuticals, Inc.
Market Cap
$1.54B
Gross Margin
97.47%
TTM Avg
97.18%
3Y Avg
67.81%
5Y Avg
56.26%
Market Cap
$1.57B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
66.67%
Market Cap
$1.50B
Gross Margin
51.26%
TTM Avg
45.83%
3Y Avg
28.18%
5Y Avg
37.38%
Market Cap
$1.50B
Gross Margin
57.87%
TTM Avg
56.73%
3Y Avg
61.85%
5Y Avg
-49.66%
Market Cap
$1.59B
Gross Margin
53.89%
TTM Avg
45.92%
3Y Avg
-11.61%
5Y Avg
-9.29%
Market Cap
$1.49B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.48B
Gross Margin
33.71%
TTM Avg
32.28%
3Y Avg
31.46%
5Y Avg
31.45%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.54B | 97.47% | 97.18% | 67.81% | 56.26% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 73.09% | 81.06% | 86.06% | 90.71% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | 100.00% | 100.00% | 100.00% | 66.67% |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 51.26% | 45.83% | 28.18% | 37.38% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 57.87% | 56.73% | 61.85% | -49.66% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | 53.89% | 45.92% | -11.61% | -9.29% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | 0.00% | 0.00% | 0.00% | 0.00% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 33.71% | 32.28% | 31.46% | 31.45% |
| uniQure N.V. (QURE)vs › | $1.60B | 89.53% | 60.98% | 58.20% | 16.96% |
| GH Research PLC (GHRS)vs › | $1.48B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
97.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 95.59% |
| 2026-03-31 | 95.94% |
| 2025-12-31 | 102.30% |
| 2025-09-30 | 95.42% |
| 2025-06-30 | 96.63% |
| 2025-03-31 | 95.58% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 99.90% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 99.74% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | 100.00% |
| 2016-06-30 | 100.00% |
| 2016-03-31 | 100.00% |
| 2015-12-31 | 100.00% |
| 2015-09-30 | 100.00% |
| 2015-06-30 | 100.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 50.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
